Updated:
Three Manufacturing Sites From UCB
The firm, named Three Manufacturing Sites From UCB, appears to have been formed from the carve-out of three manufacturing plants owned by the Belgian...
Three Manufacturing Sites From UCB
The firm, named Three Manufacturing Sites From UCB, appears to have been formed from the carve-out of three manufacturing plants owned by the Belgian pharmaceutical company UCB. Its headquarters are in Monheim, Germany, a location consistent with UCB's historical manufacturing presence in the region. The entity's exact founding date and ownership structure remain unclear from public sources. The entity's core activity is the manufacturing of pharmaceutical products. These include active pharmaceutical ingredients (APIs) and finished drug products, supplied to UCB and potentially other third-party clients. The asset base comprises three production sites, likely focused on different stages of the pharmaceutical manufacturing process. The geographic footprint centers on Europe, specifically Germany, with the sites integrated into the broader UCB supply chain. Team size and total deployment figures are not publicly available. The entity may function as a standalone manufacturing contractor or as an asset-holding entity for UCB, depending on the terms of the carve-out. No recent operational events have been reported in the past 24 months. A key structural differentiator is the entity's formation as a carve-out from a major pharmaceutical company, UCB. This suggests a strategy of separating manufacturing assets from the parent's R&D and commercial operations, a trend seen in the pharmaceutical industry to streamline operations and reduce fixed costs.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Monheim
Corporate office
Monheim, Germany
Sector focus
Frequently asked questions
What does Three Manufacturing Sites From UCB do exactly?
The entity operates three pharmaceutical manufacturing sites, likely producing active pharmaceutical ingredients and finished drug products. It was formed from UCB, a Belgian biopharma company, and serves as a contract manufacturing organization (CMO) or an internal supplier for UCB's global supply chain.
Where are the manufacturing sites located?
The entity's headquarters are in Monheim, Germany, indicating the sites are likely in Germany. UCB historically has manufacturing in Monheim and other German locations, though the specific addresses of the three sites are not publicly listed.
Is this entity a contract manufacturing organization (CMO) or a captive operation?
Its status is ambiguous. The name suggests a carve-out, which may imply it operates as a standalone entity contracted to UCB and potentially other pharma companies. However, the lack of ownership disclosure leaves it unclear if it is truly independent or still integrated with UCB.
What is the relationship between this entity and UCB, the parent company?
The entity was formed from three manufacturing sites originally owned by UCB. The exact relationship — whether it is a wholly owned subsidiary, a spin-off sold to a private equity firm, or a joint venture — is not publicly documented.
Does the entity produce any specific drugs or therapeutic areas?
There is no public information specifying which drugs are manufactured at these sites. UCB specializes in neurology and immunology, so the sites may produce medications for conditions like epilepsy, Parkinson's disease, or rheumatoid arthritis.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: